Salivary binding antibodies induced by human immunodeficiency virus type 1 recombinant gp120 vaccine. The NIAID AIDS Vaccine Evaluation Group.
Salivary binding antibodies induced by candidate human immunodeficiency virus type 1 (HIV-1) vaccines in healthy, HIV-1 uninfected volunteers were assessed in a clinical trial evaluating intramuscularly injected HIV-1MN recombinant gp120 (rgp120) vaccine alone or with HIV-1IIIB rgp120 vaccine. The two rgp120 vaccines induced envelope glycoprotein-specific immunoglobulin G (IgG) and IgA antibodies in whole saliva and serum.
Gorse
G J
GJ
Department of Internal Medicine, Saint Louis University School of Medicine, Missouri, USA.
Yang
E Y
EY
Belshe
R B
RB
Berman
P W
PW
D016915:AIDS Vaccines / Q000276:immunology*; D001667:Binding, Competitive / Q000276:immunology; D005260:Female; D015483:HIV Antibodies / Q000032:analysis / Q000096:biosynthesis* / Q000276:immunology*; D015699:HIV Envelope Protein gp120 / Q000008:administration & dosage / Q000276:immunology*; D006801:Humans; D007273:Injections, Intramuscular; D008297:Male; D012463:Saliva / Q000276:immunology*; D014614:Vaccines, Synthetic / Q000276:immunology*
D016915:AIDS Vaccines; D015483:HIV Antibodies; D015699:HIV Envelope Protein gp120; D014614:Vaccines, Synthetic